SSRI Antidepressant Medications: Adverse Effects and Tolerability
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Side effects of antidepressants can be predicted by receptor selectivity and site of action. Although the selective serotonin reuptake inhibitors (SSRIs) have better overall safety and tolerability than older antidepressants, broad-based experience with SSRIs has shown the frequency and type of side effects to be increased relative to clinical trial data. The author explores the reasons for the different profiles and discusses adverse effects, especially sexual dysfunction, weight gain, and sleep disturbance, the most troubling adverse events seen during long-term SSRI therapy. The informed management of these side effects by primary care practitioners supports successful treatment of depression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It has been routinely identified to cause less severe withdrawal effects than other SSRIs, which has been attributed to its longer half-life 3,30,75 .”
From Tapering of SSRI treatment to mitigate withdrawal symptoms (2019) · cites this paper as [75]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However many of these drugs can acutely induce adverse side effects including anxiety and increased risk of suicidal behaviors (Ferguson, 2001; Gartlehner et al., 2011; Vaswani et al., 2003).”
From Molecular and anatomical organization of the dorsal raphe nucleus (2019) · cites this paper as Ferguson, 2001
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“During long-term use of SSRIs, the most troubling adverse effects seem to be gastrointestinal problems, sleep disturbances and sexual dysfunction,49”
From Should antidepressants be used for major depressive disorder? (2020) · cites this paper as [49]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“often intolerable side-effects”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [260]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“many patients refusing to take traditional antidepressants due to their side-effects”
From Psychedelics and Other Psychoplastogens for Treating Mental Illness. (2021) · cites this paper as [260]
Experimental — accuracy not yet measured
3 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Arky, R. A. (1994) · Cited by 2,632
The Arizona Sexual Experience Scale (ASEX): Reliability and Validity
A. McGahuey, A. J. G. (2000) · Journal of Sex & Marital Therapy · doi:10.1080/009262300278623 · Cited by 1,155
Effects of SSRIs on Sexual Function: A Critical Review
Rosen, R. C., Lane, R. M., & Menza, M. (1999) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-199902000-00013 · Cited by 650
1995 Physicians' Desk Reference
Schild, S. M. (1995) · AORN Journal · doi:10.1016/s0001-2092(06)63819-2 · Cited by 497
Systematic Review and Guide to Selection of Selective Serotonin Reuptake Inhibitors
Edwards, J. G., & Anderson, I. (1999) · Drugs · doi:10.2165/00003495-199957040-00005 · Cited by 458
Mechanism of action of antidepressant medications.
Feighner, J. P. (1999) · PubMed · Cited by 323
Anderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+<1::aid-da1>3.3.co;2-j · Cited by 278
Anderson, I. M. (1998) · Depression and Anxiety · doi:10.1002/(sici)1520-6394(1998)7:1+<11::aid-da4>3.0.co;2-i · Cited by 266
Spigset, O. (1999) · Drug Safety · doi:10.2165/00002018-199920030-00007 · Cited by 225
Anorgasmia from Clomipramine in Obsessive-Compulsive Disorder: A Controlled Trial
Monteiro, W. O., Noshirvani, H. F., Marks, I. M., & Lelliott, P. T. (1987) · British Journal of Psychiatry · doi:10.1192/bjp.151.1.107 · Cited by 201
Cited by
Items 101–200 of 670
Pollok, J., van Agteren, J. E., & Carson-Chahhoud, K. V. (2018) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd012346.pub2 · Cited by 59
“[DOI: 10.4088/PCC.09m00858gry] Ferguson 2001 Ferguson JM. SSRI antidepressant medications: adverse eHects and tolerability.”
BackgroundInfluentialZhou, C., Fang, L., Chen, Y., Zhong, J., Wang, H., & Xie, P. (2018) · Osteoporosis International · doi:10.1007/s00198-018-4413-0 · Cited by 59
“Selective serotonin reuptake inhibitors (SSRIs), which inhibit the reuptake of both serotonin and noradrenaline, are the most commonly prescribed class of antidepressants worldwide [1].”
BackgroundOff-label uses of drugs for depression
Skånland, S. S., & Cieślar‐Pobuda, A. (2019) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2019.172732 · Cited by 63
Assessment of the Antidepressant Side Effects Occurrence in Patients Treated in Primary Care
Ramić, E., Prasko, S., Gavran, L., & Spahić, E. (2020) · Materia Socio Medica · doi:10.5455/msm.2020.32.131-134 · Cited by 79
“001 rarely 91 (18) insignificant 84 (17)”
Hansen, C. H., Larsen, L. W., Sørensen, A. M., Halling‐Sørensen, B., & Styrishave, B. (2017) · Toxicology in Vitro · doi:10.1016/j.tiv.2017.02.001 · Cited by 62
“Some of these effects are nausea, dry mouth, appetite changes and sexual dysfunction (Ferguson, 2001).”
BackgroundHein, M., Lanquart, J., Loas, G., Hubain, P., & Linkowski, P. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.09.016 · Cited by 64
Evens, R., Schmidt, M. E., Majić, T., & Schmidt, T. T. (2023) · Therapeutic Advances in Psychopharmacology · doi:10.1177/20451253231172254 · Cited by 56
“These subacute side effects are comparable to the known side effects of selective serotonin reuptake inhibitors (SSRIs), 75 the drug class most commonly used in treating depression and anxiety.”
BackgroundYin, W., Mei, L., Sun, T., Wang, Y., Li, J., Chen, C., Farzinpour, Z., Mao, Y., Tao, W., Li, J., et al. (2020) · Anesthesiology · doi:10.1097/aln.0000000000003133 · Cited by 60
Voltammetric and mathematical evidence for dual transport mediation of serotonin clearancein vivo
Wood, K. M., Zeqja, A., Nijhout, H. F., Reed, M. C., Best, J. A., & Hashemi, P. (2014) · Journal of Neurochemistry · doi:10.1111/jnc.12733 · Cited by 53
Impact of pharmacological agents on mitochondrial function: a growing opportunity?
Stoker, M. L., Newport, E., Hulit, J., West, A. P., & Morten, K. (2019) · Biochemical Society Transactions · doi:10.1042/bst20190280 · Cited by 56
Paroxetine: current status in psychiatry
Pae, C.-U., & Patkar, A. A. (2007) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.7.2.107 · Cited by 53
Rifkin-Zybutz, R. P., Erridge, S., Holvey, C., Coomber, R., Gaffney, J., Lawn, W., Barros, D. A. R., Bhoskar, U., Mwimba, G., Praveen, K., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06399-3 · Cited by 53
“Additionally, SSRIs can take up to 12 weeks to be effective in anxiety disorders, can cause an initial increase in anxiety and, although generally well tolerated, have a significant side effect profile which limits tolerability in some individuals (Ferguson 2001).”
BackgroundShafiee, A., Jafarabady, K., Seighali, N., Mohammadi, I., Firouzabadi, S. R., Abhari, F. S., & Bakhtiyari, M. (2024) · Nutrition Reviews · doi:10.1093/nutrit/nuae076 · Cited by 61
The chemokine CXCL1 and its receptor CXCR2 contribute to chronic stress‐induced depression in mice
Chai, H., Fu, X., Ma, L., Sun, H., Chen, G., Song, M., Chen, W., Chen, Y., Tan, M., Guo, Y., et al. (2019) · The FASEB Journal · doi:10.1096/fj.201802359rr · Cited by 50
“All n = 3, Student’s t test, t(4) = 8.”
Use of Serotonergic Antidepressants and Bleeding Risk in Patients Undergoing Surgery
Jeong, B.-O., Kim, S., Kim, S., Kim, J., Shin, I., & Yoon, J. (2013) · Psychosomatics · doi:10.1016/j.psym.2013.08.011 · Cited by 51
Efficacy of Silexan in subthreshold anxiety: meta-analysis of randomised, placebo-controlled trials
Möller, H.-J., Volz, H.-P., Dienel, A., Schläfke, S., & Kasper, S. (2019) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-017-0852-4 · Cited by 49
“Other common side effects of SSRIs and/or hydroxyzine include anticholinergic reactions, gastrointestinal disturbances, weight gain, sexual dysfunction, or agitation and irritability [41, 42].”
BackgroundSolomon, D., Adams, J., & Graves, N. (2013) · Journal of Affective Disorders · doi:10.1016/j.jad.2012.11.064 · Cited by 54
“Consequently, research has focussed on the development of drugs with improved safety and tolerability (Ferguson, 2001) to offset this detriment to both patient outcomes and health costs.”
BackgroundHu, Z., Ching, L. W., Hui-juan, L., Liang, Y., Zhiyu, W., Weiyang, H., Zhaoxiang, B., & Zhong, L. L. D. (2021) · Scientific Reports · doi:10.1038/s41598-021-88263-y · Cited by 55
7,8-Dihydroxyflavone as a pro-neurotrophic treatment for neurodevelopmental disorders
Du, X., & Hill, R. (2015) · Neurochemistry International · doi:10.1016/j.neuint.2015.07.021 · Cited by 51
Nature-Based Recreational Therapy for Military Service Members: A Strengths Approach
Hawkins, B. L., Townsend, J. A., & Garst, B. A. (2016) · Therapeutic Recreation Journal · doi:10.18666/trj-2016-v50-i1-6793 · Cited by 47
Pashaei, Y. (2021) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2021.03.010 · Cited by 50
“the serotonergic synaptic cleft and can stimulate postsynaptic receptors for a more extended period [56].”
BackgroundChallenging Received Wisdom: Antidepressants and the Placebo Effect
Kirsch, I. (2020) · McGill Journal of Medicine · doi:10.26443/mjm.v11i2.571 · Cited by 45
“It means that improvement can be obtained without reliance on addictive drugs with potentially serious side effects (15, 16).”
BackgroundMeister, R., von Wolff, A., Mohr, H., Nestoriuc, Y., Härter, M. C., Hölzel, L. P., & Kriston, L. (2015) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2015.10.007 · Cited by 48
Nishimura, A., Aritomi, Y., Sasai, K., Kitagawa, T., & Mahableshwarkar, A. R. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12565 · Cited by 45
Hieronymus, F., Lisinski, A., Nilsson, S., & Eriksson, E. (2018) · Molecular Psychiatry · doi:10.1038/mp.2017.147 · Cited by 44
Fighting against depression with TREK-1 blockers: Past and future. A focus on spadin
Djillani, A., Piétri, M., Mazella, J., Heurteaux, C., & Borsotto, M. (2018) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2018.10.003 · Cited by 46
Is tDCS a potential first line treatment for major depression?
Woodham, R. D., Rimmer, R. M., Mutz, J., & Fu, C. H. Y. (2021) · International Review of Psychiatry · doi:10.1080/09540261.2021.1879030 · Cited by 51
Pankiewicz, P., Szybiński, M., Kisielewska, K., Gołębiowski, F., Krzemiński, P., Rutkowska-Włodarczyk, I., Moszczyński-Pętkowski, R., Gurba-Bryśkiewicz, L., Delis, M., Mulewski, K., et al. (2021) · Pharmaceuticals · doi:10.3390/ph14080704 · Cited by 42
“These may include side effects such as insomnia, sleepiness, and weight gain [10], and limited efficacy in drug-resistant forms of the disease [11].”
BackgroundPhenolic Acids as Antidepressant Agents
Cordeiro, M. L. D. S., Aquino-Martins, V. G. D. Q., da Silva, A. P., Rocha, H. A. O., Soares-Rachetti, V. D. P., & Scortecci, K. C. (2022) · Nutrients · doi:10.3390/nu14204309 · Cited by 55
“Moreover, side effects, such as sexual dysfunction, weight gain, sleep disorders, dizziness, nausea, and lethargy lead to treatment dropout [4,17].”
BackgroundAntidepressant Drug Sertraline against Human Cancer Cells
Duarte, D., & Vale, N. (2022) · Biomolecules · doi:10.3390/biom12101513 · Cited by 56
Chimenti, M. S., Fonti, G. L., Conigliaro, P., Triggianese, P., Bianciardi, E., Coviello, M., Lombardozzi, G., Tarantino, G., Niolu, C., Siracusano, A., et al. (2021) · Annals of General Psychiatry · doi:10.1186/s12991-020-00322-2 · Cited by 52
“hand, psychotropic drugs used in the management of patients may exacerbate the level of fatigue [82] and interact with treatments commonly used for arthritis management, such as NSAIDs and DMARDs [83].”
BackgroundAdamo, D., Pecoraro, G., Coppola, N., Calabria, E., Aria, M., & Mignogna, M. D. (2020) · Oral Diseases · doi:10.1111/odi.13602 · Cited by 50
Sexual Touching and Difficulties with Sexual Arousal and Orgasm Among U.S. Older Adults
Galinsky, A. M. (2011) · Archives of Sexual Behavior · doi:10.1007/s10508-011-9873-7 · Cited by 52
Smith, S. R., Garvey, W. T., Greenway, F. L., Zhou, S., Fain, R., Pilson, R., Fujioka, K., & Aronne, L. J. (2017) · Obesity · doi:10.1002/oby.21811 · Cited by 42
“Nine commonly observed AEs in patients taking lorcaserin are potentially associated with serotonin effects and/or commonly attributable to use of selective serotonin reuptake inhibitors (9,18) and were prespecified as potential serotonergic AEs in this study.”
BackgroundMethodRazavi, B. M., Sadeghi, M., Abnous, K., Hassani, F. V., & Hosseinzadeh, H. (2017) · PubMed Central · Cited by 44
Khanassov, V., Hu, J., Reeves, D., & van Marwijk, H. (2018) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.4974 · Cited by 44
“1689 over other antidepressants (eg, tricyclics) is due to their broad indications, safer side effect profile, and efficacy.(4) However, the use of SSRIs may be associated with a higher risk for all types of fractures compared with no SSRI use, which may be a particular concern in older patients.”
BackgroundTools for managing feline problem behaviours: Psychoactive medications
Denenberg, S., & Dube, M. B. (2018) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x18806760 · Cited by 46
Bappi, M. H., Prottay, A. A. S., Kamli, H. M., Sonia, F. A., Mia, M. N., Akbor, M. S., Hossen, M. M., Awadallah, S. M., Mubarak, M. S., & Islam, M. T. (2023) · Molecules · doi:10.3390/molecules28145616 · Cited by 41
“In contrast, at high doses, anti-depressant drugs also cause some serious adverse events such as GI disturbances, pain, anxiety, nausea, agit tion, insomnia, and many more [52].”
BackgroundA review of current evidence for vilazodone in major depressive disorder
Wang, S.-M., Han, C., Lee, S.-J., Patkar, A. A., Masand, P. S., & Pae, C.-U. (2013) · International Journal of Psychiatry in Clinical Practice · doi:10.3109/13651501.2013.794245 · Cited by 37
“A minimal weight gain seen in the pivotal trials and open-label long-term study is noteworthy (Administration 2012; Ferguson 2001) because weight gain is one of major leading causes of noncompliance during antidepressant treatment (Trivedi et al. 2007).”
BackgroundThe neuroscience and context of adolescent depression
Henje, E., Ho, T. C., Connolly, C. G., LeWinn, K. Z., Sacchet, M. D., Tymofiyeva, O., Weng, H. Y., & Yang, T. T. (2016) · Acta Paediatrica · doi:10.1111/apa.13299 · Cited by 54
“Several SSRI side effects may be especially problematic for teenagers, such as weight gain, sexual dysfunction and sleep disturbances, which may impede both social functioning and overall health (18).”
BackgroundKhushboo, Siddiqi, N. J., Pereira, M. D. L., & Sharma, B. (2022) · Molecular Neurobiology · doi:10.1007/s12035-022-02780-z · Cited by 47
“Various antagonists of these receptors have been shown to exert AD-like effects [34, 74, 75].”
BackgroundInfluentialThe Effects of CYP2C19 Genotype on Proxies of SSRI Antidepressant Response in the UK Biobank
Wong, W. L. E., Fabbri, C., Laplace, B., Li, D., van Westrhenen, R., Lewis, C. M., Dawe, G. S., & Young, A. H. (2023) · Pharmaceuticals · doi:10.3390/ph16091277 · Cited by 43
“Among the classes of antidepressants available, selective serotonin reuptake inhibitors (SSRIs) have been a standard treatment option for several decades, a status attributable to the substantial evidence base that supports their effectiveness and safety [6,7].”
Fang, Z., Li, K., Li, Y., Zhang, H., Jones, K. C., Liu, X., Liu, S., Ma, L. Q., & Luo, J. H. (2019) · Environmental Science & Technology · doi:10.1021/acs.est.9b03166 · Cited by 40
Laiou, P., Kaliukhovich, D. A., Folarin, A., Ranjan, Y., Rashid, Z., Conde, P., Stewart, C., Sun, S., Zhang, Y., Matcham, F., et al. (2022) · JMIR mhealth and uhealth · doi:10.2196/28095 · Cited by 51
“Antidepressants may cause a wide range of side effects, including headaches, fatigue, weight gain, drowsiness, and dizziness [29,30].”
BackgroundWal, J. S. V., Maraldo, T. M., Vercellone, A. C., & Gagne, D. A. (2015) · Appetite · doi:10.1016/j.appet.2015.01.024 · Cited by 43
“Further, the symptoms of NES may not remit or remit fully, and SSRIs may be accompanied by side effects, particularly sexual dysfunction, weight gain, and sleep disturbance (Ferguson, 2001).”
BackgroundDjillani, A., Piétri, M., Moréno, S., Heurteaux, C., Mazella, J., & Borsotto, M. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00643 · Cited by 39
“The absence of adverse effects differentiates spadinanalogs from other antidepressant drugs, such as SSRIs, SNRIs, tricyclics (Ferguson, 2001), or ketamine (Katalinic et al.”
BackgroundNeurochemistry of Neurochemicals: Messengers of Brain Functions
Uddin, M. S., Mamun, A. A., Kabir, M. T., Nasrullah, M., Wahid, F., Begum, M. M., Labu, Z. K., Rahman, M. S., Islam, M. T., Amran, M. S., et al. (2018) · Journal of Intellectual Disability - Diagnosis and Treatment · doi:10.6000/2292-2598.2017.05.04.6 · Cited by 40
Ghazizadeh‐Hashemi, F., Bagheri, S., Ashraf‐Ganjouei, A., Moradi, K., Shahmansouri, N., Mehrpooya, M., Noorbala, A.-A., & Akhondzadeh, S. (2021) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.13276 · Cited by 40
“Additionally, 4–6 weeks of SSRI administration is needed to observe initial clinical improvements.(9) Beyond these issues, there is also inconsistent data regarding the association between SSRI and future readmission and mortality in CAD patients.”
BackgroundBarton, S., Karner, C., Salih, F., Baldwin, D. S., & Edwards, S. J. (2014) · Health Technology Assessment · doi:10.3310/hta18500 · Cited by 36
“Selective serotonin reuptake inhibitors are the first choice of pharmacological treatment for anxiety disorders and major depression because they have a better tolerability and adverse effect profile than other classes of antidepressants.(72) In particular, compared with TCAs, the SSRIs do not cause cardiac conduction…”
Pharmacological Treatment of Generalized Anxiety Disorder
Baldwin, D. S., Ajel, K. I., & Garner, M. J. (2009) · Current topics in behavioral neurosciences · doi:10.1007/7854_2009_2 · Cited by 48
“Weight gain may be less troublesome with SSRIs than with many other psychotropic drugs, but the potential for gaining weight can cause concern in many patients, and there is reasonable evidence that some SSRIs can cause increases in weight of 6–10 kg after 6–12 months of treatment (Ferguson 2001).”
BackgroundKetamine as Antidepressant? Current State and Future Perspectives
Hasselmann, H. (2013) · Current Neuropharmacology · doi:10.2174/1570159x113119990043 · Cited by 43
Guo, M., Etminan, M., Procyshyn, R. M., Kim, D. D., Samii, A., Kezouh, A., & Carleton, B. (2018) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000911 · Cited by 43
Jung, E.-J., Kang, Y. P., Yoon, I., Kim, J., Kwon, S. W., Chung, S., Shim, C., & Kim, D. (2013) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2013.08.080 · Cited by 35
Zhao, W., Hylton, N. K., Wang, J. P., Chindavong, P. S., Alural, B., Kurtser, I., Subramanian, A., Mazitschek, R., Perlis, R. H., & Haggarty, S. J. (2019) · Molecular and Cellular Neuroscience · doi:10.1016/j.mcn.2019.06.006 · Cited by 41
Amaghnouje, A., Mechchate, H., Es-safi, I., Boukhira, S., Aliqahtani, A. S., Noman, O. M., Nasr, F. A., Conte, R., Calarco, A., & Bousta, D. (2020) · Molecules · doi:10.3390/molecules25235653 · Cited by 39
“Side effects, such as sexual dysfunction, coronary heart disease, and fracture risk, have been reported using these antidepressants [8], one of these being is paroxetine.”
BackgroundHieronymus, F., Lisinski, A., Eriksson, E., & Østergaard, S. D. (2021) · Translational Psychiatry · doi:10.1038/s41398-021-01364-0 · Cited by 41
Sasaki, K., Ferdousi, F., Fukumitsu, S., Kuwata, H., & Isoda, H. (2021) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2021.112291 · Cited by 44
Potential Role of the Antidepressants Fluoxetine and Fluvoxamine in the Treatment of COVID-19
Mahdi, M., Hermán, L., Réthelyi, J., & Bálint, B. L. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23073812 · Cited by 37
Sultana, J., Italiano, D., Spina, E., Cricelli, C. A., Lapi, F., Pecchioli, S., Gambassi, G., & Trifirò, G. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-013-1636-z · Cited by 38
Kim, J., Lei, Y., Lu, X.-Y., & Kim, C. S. (2022) · Molecular Psychiatry · doi:10.1038/s41380-022-01682-9 · Cited by 33
“However, after the initial pharmacologic treatment, only around 20–30% of patients with PTSD satisfy remission criteria [91, 92].”
BackgroundGlucose Tolerance in Patients with Narcolepsy
Beitinger, P. A., Fulda, S., Dalal, M. A., Wehrle, R., Keckeis, M., Wetter, T. C., Han, F., Pollmächer, T., & Schuld, A. (2012) · SLEEP · doi:10.5665/sleep.1628 · Cited by 34
Martin, L. F., Moutal, A., Cheng, K., Washington, S. M., Calligaro, H., Goel, V., Kranz, T., Largent‐Milnes, T. M., Khanna, R., Patwardhan, A. M., et al. (2021) · Journal of Pain · doi:10.1016/j.jpain.2021.05.006 · Cited by 36
Manepalli, S., Geffert, L. M., Surratt, C. K., & Madura, J. D. (2011) · Journal of Chemical Information and Modeling · doi:10.1021/ci200280m · Cited by 36
Emerging treatments for the behavioral and psychological symptoms of dementia
Anand, A., Khurana, P., Chawla, J. S., Sharma, N., & Khurana, N. (2017) · CNS Spectrums · doi:10.1017/s1092852917000530 · Cited by 41
Gobshtis, N., Ben‐Shabat, S., & Fride, E. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.028 · Cited by 34
Efficacy of Acupuncture Treatment of Sexual Dysfunction Secondary to Antidepressants
Khamba, B., Aucoin, M., Lytle, M., Vermani, M., Maldonado, A., Iorio, C., Cameron, C., Tsirgielis, D., D’Ambrosio, C., Anand, L., et al. (2013) · The Journal of Alternative and Complementary Medicine · doi:10.1089/acm.2012.0751 · Cited by 35
“SSRIs and SNRIs have been reported to cause sexual dysfunction, with prevalence rates as high as 50%– 90%.(8,9,10,11) Specific symptoms reported by patients include delayed orgasm, decrease sex drive, erectile dysfunction, and pain on intercourse, with the first three being the most commonly associated.”
Lu, W. Y.-R., Krellman, J. W., & Dijkers, M. P. J. M. (2016) · Neurorehabilitation · doi:10.3233/nre-151296 · Cited by 43
“Symptoms of insomnia are frequently left unaddressed in the treatment of post-TBI mood disorders despite high co-morbidity, while some anti-depressant medications, such as selective serotonin reuptake inhibitors (SSRIs), cause insomnia in some individuals (Ferguson, 2001).”
BackgroundTran, B. X., Ha, G. H., Nguyen, D. N., Nguyen, T. P., Do, H., Latkin, C. A., Ho, C. S. H., & Ho, R. (2020) · Quality of Life Research · doi:10.1007/s11136-020-02512-7 · Cited by 36
Grégoire, S., & Neugebauer, V. (2013) · Molecular Pain · doi:10.1186/1744-8069-9-41 · Cited by 36
“© 2013 Grégoire and Neugebauer; licensee Bi the Creative Commons Attribution License (ht distribution, and reproduction in any medium or inconsistent analgesic efficacy [4,6] but better overall safety and tolerability compared to tricyclic antidepressants [8].”
BackgroundZare, S., Fereidoonnezhad, M., Afshar, D., & Ramezani, Z. (2016) · Computational Biology and Chemistry · doi:10.1016/j.compbiolchem.2016.12.004 · Cited by 33
Kumar, M., Bajpai, R. C., Shaik, A. R., Srivastava, S., & Vohora, D. (2020) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-020-02893-1 · Cited by 36
Bowers, H. M., Williams, S. J., Geraghty, A. W. A., Maund, E., O’brien, W., Leydon, G., May, C. R., & Kendrick, T. (2019) · BMJ Open · doi:10.1136/bmjopen-2018-027837 · Cited by 31
“10 The side effects of antidepressants include weight gain, sexual dysfunction, sleep disturbance and gastrointestinal bleeding, which increase with longer term use.(11) SSRI use for depression in older patients is associated with increased risk of falls, fractures, seizures, stroke and hyponatraemia.”
BackgroundSani, N. A., Yusoff, S. S. M., Norhayati, M. N., & Zainudin, A. M. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20042828 · Cited by 38
“Another study revealed that many antidepressants available on the market are associated with sexual dysfunction and sleep disturbances, which are some of the most common reasons for non-adherence toward antidepressants [13,14].”
Zhang, X., Asim, M., Fang, W., Monir, H. M., Wang, H., Kim, K., Feng, H., Wang, S., Gao, Q., Lai, Y., et al. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02127-7 · Cited by 34
“According to WHO, there is a 25% increase in depression cases during the Covid-19 pandemic [1].”
BackgroundStein, D. J., Bandelow, B., Merideth, C., Olausson, B., Szamosi, J., & Eriksson, H. (2011) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.1256 · Cited by 38
Tien, T. T., Dao, U. P. N., Bui, H. T., & Nguyen, T. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.07.001 · Cited by 36
Zulfarina, M. S., Syarifah-Noratiqah, S.-B., Shuid, A. N., Sharif, R., & Mohamed, I. N. (2019) · Clinical Psychopharmacology and Neuroscience · doi:10.9758/cpn.2019.17.2.145 · Cited by 36
“, 1999 NaSSA Mirtazapine (30-45) Non-controlled Effective Boshuisen et al.”
BackgroundBowers, H. M., Kendrick, T., Głowacka, M., Williams, S. J., Leydon, G., May, C. R., Dowrick, C. F., Moncrieff, J., Laine, R., Nestoriuc, Y., et al. (2020) · BMJ Open · doi:10.1136/bmjopen-2019-032312 · Cited by 34
Anti-anxiety Properties of Selected Medicinal Plants
Khan, A., Akram, M., Thiruvengadam, M., Daniyal, M., Zakki, S. A., Munir, N., Zainab, R., Heydari, M., Mosavat, S. H., Ребезов, М. Б., et al. (2021) · Current Pharmaceutical Biotechnology · doi:10.2174/1389201022666210122125131 · Cited by 40
Sustained Modulation of Deep Brain Circuits with Focused Ultrasonic Waves
Webb, T. D., Wilson, M. G., Odéen, H., & Kubanek, J. (2022) · Brain stimulation · doi:10.1016/j.brs.2023.04.012 · Cited by 35
Wang, J. T., Hoffman, B. M., & Blumenthal, J. A. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.513701 · Cited by 32
“After the acute phase of treatment, SSRI side effects are less common, and the rate of treatment dropout due to side effects is comparable to placebo [72,88].”
BackgroundNew perspectives in the treatment of body dysmorphic disorder
Hong, K., Nezgovorova, V., & Hollander, E. (2018) · F1000Research · doi:10.12688/f1000research.13700.1 · Cited by 31
A New Paradigm for Achieving a Rapid Antidepressant Response
Malhi, G. S., Morris, G., Bell, E., & Hamilton, A. (2020) · Drugs · doi:10.1007/s40265-020-01303-1 · Cited by 34
Marasine, N. R., Sankhi, S., Lamichhane, R., Marasini, N. R., & Dangi, N. B. (2020) · Depression Research and Treatment · doi:10.1155/2020/7024275 · Cited by 44
“The reason behind the frequent use of SSRIs compared to TCAs might be fewer side effects and better tolerability offered by SSRIs than the latter [19].”
BackgroundMusazadeh, V., Zarezadeh, M., Faghfouri, A. H., Keramati, M., Ghoreishi, Z., & Farnam, A. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105963 · Cited by 33
Cui, C., & Kaartinen, M. T. (2014) · Bone · doi:10.1016/j.bone.2014.11.008 · Cited by 31
“Mounting evidence shows negative peripheral side effects of SSRIs, which include problems in the gastrointestinal and cardiovascular systems, as well as in bone mass accrual and bone quality [7–9].”
BackgroundSun, J. W., Hernández–Díaz, S., Haneuse, S., Bourgeois, F. T., Vine, S. M., Olfson, M., Bateman, B. T., & Huybrechts, K. F. (2020) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2020.2762 · Cited by 32
Genetics of Human Sleep Behavioral Phenotypes
Hsu, P.-K., Ptáček, L. J., & Fu, Y.-H. (2015) · Methods in Enzymology · doi:10.1016/bs.mie.2014.10.046 · Cited by 29
“…disorders are known to affect sleep patterns, whereas a wide spectrum of over-the-counter drugs (e.g., melatonin), prescription drugs (e.g., SSRI; Ferguson, 2001), and commonly consumed foods and beverages (e.g., coffee, alcohol) modulate alertness/sleepiness levels and evenmodulate the…”
BackgroundInfluentialGayathri, D., & Rashmi, B. S. (2017) · Mental Health & Prevention · doi:10.1016/j.mhp.2017.01.003 · Cited by 34
Gupta, P., Sagar, R., & Mehta, M. (2019) · Asian Journal of Psychiatry · doi:10.1016/j.ajp.2019.07.034 · Cited by 35
Dougherty, R. F., Clarke, P., Atli, M., Kuc, J., Schlosser, D. A., Dunlop, B. W., Hellerstein, D. J., Aaronson, S. T., Zisook, S., Young, A. H., et al. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06432-5 · Cited by 35
Efficacy and Safety of Psychedelics in Treating Anxiety Disorders
Feulner, L., Sermchaiwong, T., Rodland, N., & Galarneau, D. W. (2023) · Ochsner Journal · doi:10.31486/toj.23.0076 · Cited by 34
“15 These adverse reactions and delayed effects often lead to nonadherence.”
BackgroundPharmacokinetics of Vilazodone in Patients with Mild or Moderate Renal Impairment
Boinpally, R., Alcorn, H. W., Adams, M. H., Longstreth, J. A., & Edwards, J. G. (2013) · Clinical Drug Investigation · doi:10.1007/s40261-013-0061-5 · Cited by 28
“Diarrhoea was the most commonly reported adverse event; this is not unexpected considering the selective serotonin receptor inhibitor (SSRI) properties of vilazodone [13, 14].”
BackgroundGoodspeed, A. E., Kostman, N., Kriete, T. E., Longtine, J. W., Smith, S. M. C., Marshall, P., Williams, W., Clark, C., & Blakeslee, W. W. (2019) · Annals of General Psychiatry · doi:10.1186/s12991-019-0237-3 · Cited by 28
Ye, T., Wang, D., Cai, Z., Tong, L., Chen, Z., Lu, J., Lu, X., Huang, C., & Yuan, X. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108132 · Cited by 31
‘Never change a winning team’: GPs’ perspectives on discontinuation of long-term antidepressants
Leeuwen, E. V., Anthierens, S., van Driel, M., Sutter, A. D., van den Branden, E., & Christiaens, T. (2021) · Scandinavian Journal of Primary Health Care · doi:10.1080/02813432.2021.2006487 · Cited by 30
Selective serotonin reuptake inhibitors and inflammatory bowel disease; Beneficial or malpractice
Hatamnejad, M. R., Baradaran Ghavami, S., Shirvani, M., Asghari Ahmadabad, M., Shahrokh, S., Farmani, M., Sherkat, G., Asadzadeh Aghdaei, H., & Zali, M. R. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.980189 · Cited by 28
A Review of Vilazodone, Serotonin, and Major Depressive Disorder
Pierz, K. A., & Thase, M. E. (2014) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.13r01554 · Cited by 34
Stress – (self) eating: Epigenetic regulation of autophagy in response to psychological stress
Puri, D., & Subramanyam, D. (2019) · FEBS Journal · doi:10.1111/febs.14826 · Cited by 26
Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review
Landgren, V., Savard, J., Dhejne, C., Jokinen, J., Arver, S., Seto, M. C., & Rahm, C. (2022) · Drugs · doi:10.1007/s40265-022-01696-1 · Cited by 32
“Sexual dysfunctions caused by SSRIs appear to be attributable to activation of postsynaptic 5-HT2 receptors, and include orgasmic delay, anorgasmia, and decreased libido [58].”
Background
Metadata
- Authors
- Ferguson, J. M.
- Affiliations
- University of Utah (US)
- Corresponding author
- Ferguson, James M.
- ORCID
- Ferguson, James M.
- Venue
- The Primary Care Companion For CNS Disorders
- Publisher
- Physicians Postgraduate Press, Inc
- Published
- 2001-02-01
- Volume
- 3
- Issue
- 1
- Pages
- 22-27
- ISSN
- 2155-7772 (ISSN-L)
- 2155-7780
- PMC
- PMC181155
- OpenAlex
- W2024985387
- Cited by
- 669
- References
- 23
- Citations by year
- 2026: 26 · 2025: 35 · 2024: 33 · 2023: 46 · 2022: 63 · 2021: 69 · 2020: 56 · 2019: 64 · 2018: 45 · 2017: 47 · 2016: 36 · 2015: 28 · 2014: 27 · 2013: 24 · 2012: 11
- FWCI
- 0.89
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Primary Care Companion For CNS Disorders (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Social Sciences › Psychology › Clinical Psychology › Psychological Treatments and Disorders
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Keywords
- selective serotonin reuptake inhibitors, antidepressant side effects, sexual dysfunction, weight gain, sleep disorders, depression treatment, primary care management
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.